Q&A with Provectus Biopharmaceutical’s COO/CFO, Peter Culpepper

Print E-mail
By Dusty Garza   
Thursday, 16 October 2014 15:18

Provectus Biopharmaceuticals, Inc., (NYSE MKT: PVCT) specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects.

Read more...
 

Rexahn's New Nanotechnology Patent Creates Next-Generation Docetaxel, Gemcitabine, and Cisplatin

Print E-mail
By Sharon di Stefano   
Wednesday, 08 October 2014 18:11

Targeted cancer therapy is a revolution in drug company research, and Rexahn Pharmaceuticals, Inc. (RNN:NYSE MKT), recent recipient of a notice of allowance from the US Patent and Trademark Office for a new delivery platform,  might one day join the league of bigger players.

Read more...
 

Biotech Investors Gamble on Ebola Stocks

Print E-mail
By M.E.Garza   
Tuesday, 07 October 2014 04:02

The recent outbreaks of Ebola in Africa and the first case found in the U.S. have also heightened the FDA’s awareness of disease outbreaks and the need for stronger safety measures, but nothing gets investors salivating more that and constant media attention.

Read more...
 

Akebia Therapeutic' Trade Pattern and Catalyst

Print E-mail
By M.E.Garza   
Thursday, 02 October 2014 07:27
icon_tradethesisAnemia is common among patients with Chronic Kidney Disease (CKD) and end stage renal disease (ESRD). It is estimated that about 1.8 million people in the U.S. have anemia associated with chronic kidney disease.
Read more...
 

United Therapeutics Points to Pluristem's PLX-PAD as its Most Transformative Product

Print E-mail
By Sharon di Stefano   
Wednesday, 17 September 2014 04:37
icon_HeatingUpPulmonary arterial hypertension (PAH), a progressive and life threatening illness that regrettably takes a back seat to cardiovascular disease where research is concerned, is incurable and fatal. Characterized by high blood pressure in the arteries of the lungs, the heart becomes overworked, leading to its failure. Only a handful of drugs have been developed for PAH despite its huge market size.
Read more...
 

Oramed’s Insulin Pill Superior to New Diabetes Drugs Gaining Approval

Print E-mail
By Staff and Wire Reports   
Thursday, 11 September 2014 03:47

Pharmaceutical companies are adept at rolling out new classes of drugs, despite potential harmful side effects, and Eli Lilly and Co. (LLY:NYSE) is no exception.

Read more...
 

Is Exact Sciences still a buy at these prices?

Print E-mail
By Staff and Wire Reports   
Wednesday, 20 August 2014 09:17

icon_closerlook

As biotech investors may know, the FDA approved a new genetic test from EXACT Sciences Corporation (NASDAQ:EXAS) that can help diagnose colon cancer.

Read more...
 

Are "Toxic Financings" Slaying Small Retail Investors?

Print E-mail
By Staff and Wire Reports   
Tuesday, 19 August 2014 04:32

Ironridge GlobalWhat do publicly traded biotech companies like Genetic Technologies (NASDAQ::GENE), Rosetta Genomics (NASDAQ::ROSG), MEI Pharma Inc(NASDAQ::MEIP), Advaxis, Inc.(NASDAQ::ADXS), Amarantus Bioscience (OTCMKTS:AMBS), Pressure Biosciences (OTCMKTS:PBIO), Uluru Inc. (OTCMKTS:ULUR), PositiveID Corporation (OTCMKTS:PSID), Cord Blood America Inc.(OTCMKTS:CBAI) and IntelliCell BioSciences, Inc. (OTCMKTS:SVFC) all have in common? 

Read more...
 

Analyst Accepts ALS Ice Bucket Challenge

Print E-mail
By Staff and Wire Reports   
Tuesday, 19 August 2014 01:19

icon_newslinkRajesh Patel, Ph.D. of the popular site Red Acre Investments has accepted the ALS Ice Bucket Challenge which has been sweeping the nation via social media.

Read more...
 

Potential Payoffs Spuring Big Board Biotechs

Print E-mail
By Staff and Wire Reports   
Tuesday, 12 August 2014 02:59
Speculators were pushing certain big board biotechs higher as they placed their bets on potential future payoffs.
Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 47

Newsletter

BioMedReports PlasmaTech Announces Reverse Stock Split, Launches New Corporate Website; CEL-SCI Announces Closing of Public ... http://t.co/Aq9prl12iE
BioMedReports Active Stocks: IsoRay, IDEXX Laboratories, Shire plc, IGI Laboratories, Vitae Pharmaceuticals: U.S. stocks we... http://t.co/fARYOjILAh
BioMedReports Stellar Biotechnologies and Biovest International Sign KLH Supply Agreement for BiovaxID Immunotherapy for Fol... http://t.co/VxnRk1v5yZ